Nathan McNally

Part of Piper Sandler Cos., Piper Sandler Ltd. is a brokerage services provider. The company is based in London, UK. The British company was founded in 1999. Neil Robert Mackison has been the CEO of the company since 2006.

The Institute of Directors provides informative events and professional development courses. The non-profit company is based in Johannesburg, South Africa. Parmesvari Natesan has been the CEO of the South African company since 2010.

University College London Hospitals NHS Foundation Trust provides first-class acute and specialist services in six hospitals in central London, UK. The British company's mission is to deliver top-quality patient care, excellent education, and world-class research. The company also offers events, classes, and workshops at the Macmillan Support and Information Service (MSIS) and an audiological service for GPs who would like to refer patients for age-related audiological assessments. Additionally, the company provides information about the sarcoma service and hearing therapists who work with adults who have hearing loss and associated disorders, such as tinnitus and hyperacusis, and other forms of hypersensitivity. The company is ultimately controlled by the Government of United Kingdom.

HealthCor Management LP (HealthCor) is a holding firm and SEC-registered hedge fund manager headquartered in New York City. The firm was co-founded by Joseph Healey and Arthur Cohen in 2005. HealthCor provides investment management services to several privately offered pooled investment funds and institutional investors through separately managed accounts.

Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom.

Part of Axovia Therapeutics Ltd., Axovia Therapeutics, Inc. is dedicated to developing disease-transformative therapies that target key aspects of ciliopathies. The American company is working to advance gene therapy programs that have already shown early promise in treating some of the most severe aspects of bbs, such as early onset blindness and neurometabolic disease. The company was founded by Philip Beales, Victor Hernandez, and Philip Beales has been the CEO since incorporation. Axovia Therapeutics was acquired by Alsa Management Services Ltd on September 19, 2023.